Lena Biosciences introduces SeedEZ, a universal 3D cell culture system for tissue fingerprinting and drug testing

ATLANTA, GA - Mar 8, 2014 - Lena Biosciences announces the launch of its SeedEZ 3D cell culture products for tissue fingerprinting and drug testing in cancer research, ADME Tox screening, stem cell research, brain research and personalized medicine. Based on the company's Spot-a-Culture and Spot-a-Drug platform technologies, SeedEZ enables researchers to create consistent, organotypic 3D cell culture, co-culture and multilayered tissue models; deliver, localize or distribute drugs; generate gradients and test them in situ, in physiologically closer tissue analogs.

Watch engineered human liver in 3D for biotransformation of xenobiotics and toxicology http://bit.ly/1ntdNtH

SeedEZ provides a convenient framework for 3D cell-based assays, drug release studies, in vitro dosage form development and quality control testing and assurance. It was validated with diverse tissue models serving rapidly expanding high-content screening and high-throughput screening market, including liver, brain, bone and connective tissue models. SeedEZ accepts most cell types, including primary cells, cell lines and stem cells. Next, this versatile research tools enables to simulate pathological conditions, controllably introduce drugs, and systematically evaluate how specific concentrations elicit and influence cell, cell network, and tissue-like responses in normal conditions, pathological conditions and in response to drugs.

SeedEZ is a complete and exceptionally easy to use 3D cell culture and drug screening system. It enables uniform embedding or localized distribution of test compounds, excipient formulations, extracellular matrices, proteins, biomaterials, polymers used in drug delivery systems or substrates for controlled release of drugs, active and inactive biologicals, pharmaceutical reagents, biopharmaceuticals and semi-solid media. More importantly, for the first time, all this can be tested with the in situ cultured tissue equivalents.

Finally, SeedEZ is suitable for development of 3D cell culture screen analogs to point of care testing (POCT) - analogous to dried blood spots used in metabolic, infection and genetic testing. To learn more, visit http://www.lenabio.com.

About Lena Biosciences

Lena Biosciences is a privately-held life sciences company with operations in Atlanta, GA.  The company's core business is to develop novel assay platform technologies that enable basic science, pharmaceutical, and pre-clinical researchers to improve the way they grow cells, test drugs and assess function with enhanced physiological relevance. Lena Biosciences is the pioneer of Spot-A-Culture and Spot-A-Drug Platform Technologies for tissue fingerprinting in life sciences and pharmaceutical testing. These versatile tools integrate into existing pharmaceutical workflows and enable customers to model tissues, deliver and test drugs in a convenient all-in-one package. Lena Biosciences' Spot-A-Culture and Spot-A-Drug tools are compliant with medium- to high-throughput screening assays and high content screening assays for both target-based and phenotypic drug discovery and development.

For more information about Lena Biosciences please visit its website at http://www.lenabio.com.